The Filing Desk

Precigen

PGEN · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

PGEN · Last close · November 13, 2026
$4.54
Value Precigen yourself

Precigen's revenue rose 146.7% to $10 million in fiscal 2025. Its operating margin was −1,141.1%, up from −3,440.2% a year earlier. Free cash flow was −$90 million. The diluted share count rose 16.9%.

PRECIGEN, INC. Latest fiscal year ended December 31, 2025 10-K filed March 25, 2026 · 0001356090-26-000009 Updated
Revenue
$10M
146.7%
Operating margin
−1,141.1%
2299.1 pts
Net income
−$251M
 
Free cash flow
−$90M
 
Return on equity
−843.6%
682.8 pts
Market cap
$1.9B
Nov 13 close
P/E
45.4x
On $0.10 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Precigen does

Precigen is a biopharmaceutical company that develops gene-based medicines for immuno-oncology, autoimmune disorders and infectious diseases. In August 2025 the US Food and Drug Administration granted full approval to its first product, Papzimeos, for adults with recurrent respiratory papillomatosis, a rare and potentially life-threatening condition. It is caused by long-lasting infection with certain human papillomaviruses, which results in repeated benign tumors in the airways. Papzimeos is an immunotherapy that uses a harmless adenovirus to teach the immune system to attack cells infected with those viruses.

Precigen builds its medicines on its own technology platforms. AdenoVerse is the adenovirus-based one behind Papzimeos and the candidate PRGN-2009. UltraCAR-T modifies a patient's immune cells to fight cancer, and Precigen developed a device called UltraPorator to make those treatments faster and more cheaply. It continues Phase 2 trials of PRGN-2009 in cervical cancer and in oropharyngeal cancer, in agreement with the National Cancer Institute. It has finished enrolling a Phase 1b trial of PRGN-3006, and in August 2024 it paused enrollment in two other UltraCAR-T trials to focus its pipeline.

Precigen now has a product on the market, but it has lost money since it started, with the exception of 2022. It says its revenue depends largely on Papzimeos and that it has debt and will need substantial capital.

Its biggest risks, as it describes them

  • Depending heavily on the commercial success of Papzimeos in the United States and elsewhere.
  • A history of net losses, and uncertainty about reaching or keeping profitability.
  • Large future capital needs, and debt payments that could limit its operations.
  • Markets for its product and candidates that may be smaller than it estimates.
  • Early drug candidates that may fail in trials or lack regulatory approval.
From Precigen's annual report on Form 10-K, filed March 25, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Precigen lost money in fiscal 2025: a net loss of $251 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments109566398100
Debt incl. finance leases18086—093
Net debt (negative means net cash)7131—−98−7
Net debt to EBITDA—————
Debt to equity1.7x0.7x—0.0x4.5x
Interest coverage−14.5x−8.4x−213.2x−22,504.8x−28.6x
Current ratio4.5x1.5x3.0x4.8x3.1x
Quick ratio4.5x1.5x3.0x4.8x3.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Precigen's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Precigen reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score——2 of 8
Rule of 40−1,176.7%−1,992.5%−780.9%
Altman Z''−41.03−49.00−50.41
Accruals ratio−15.8%−39.2%−108.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets——Fail
Current ratio rosePassPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailFailPass
F-score——2 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Precigen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
PrecigenFY25146.7%−1,141.1%−927.6%——2
Zenas BioPharmaFY25100.0%−3,830.6%−1,723.5%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
Xenon PharmaceuticalsFY25—−4,974.3%−3,732.2%———Compare
Ovid TherapeuticsFY251,181.3%−585.2%−528.6%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue191231151913214276410
Revenue growth10.0%21.0%−34.5%−40.0%−64.7%−55.4%88.6%−76.9%−37.0%146.7%
Gross profit153198————————
Research and development112143405————495341
Operating income−125−138−506————−100−135−110
Net income−187−117−509−322−170−9228−96−126−251
Diluted EPS (US$)−1.58−0.98−3.93−2.09−1.02−0.470.14−0.39−0.47−1.37
Diluted shares (millions)118120130154167198200244268313
Cash flow
Cash from operations−49−104−124−136−77−56−65−67−68−88
Capital expenditure32474238875292
Free cash flow−81−150−166−174−85−63−70−68−77−90
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0210000000
Stock-based compensation42423619181410101011
Balance sheet at fiscal year end
Cash and short-term investments2377422275100109566398100
Debt incl. finance leases8821221817218086—093
Total assets949847716456315360216151145156
Total liabilities380300338384247252903278135
Shareholders' equity56053436372671071261183821
Margins and ratios
Gross margin80.2%85.6%————————
Operating margin−65.6%−59.7%−334.4%————−1,602.5%−3,440.2%−1,141.1%
Net margin−97.7%−50.7%−336.9%−355.3%−533.0%−646.0%105.2%−1,540.6%−3,216.2%−2,588.2%
Free cash flow margin−42.2%−65.1%−109.7%−191.6%−264.3%−441.7%−260.0%−1,099.9%−1,955.6%−927.6%
Rule of 40 (growth + FCF margin)−32.2%−44.1%−144.2%−231.6%−329.0%−497.1%−171.4%−1,176.7%−1,992.5%−780.9%
Return on capital−24.3%−26.6%−94.2%−45.4%−43.5%−51.6%−33.6%———
Return on equity−29.8%−21.4%−113.6%−148.3%−245.6%−105.6%24.2%−78.4%−160.8%−843.6%
Return on assets−19.3%−13.0%−65.2%−55.0%−44.3%−27.3%9.8%−52.3%−85.2%−166.7%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Precigen's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Precigen.